Back to companies

Stada Arzneimittel AG: Overview

Stada Arzneimittel AG (STADA), a subsidiary of Nidda Healthcare GmbH, is a manufacturer of low-cost generics and branded over the counter products. The company develops and markets drugs with off-patent active pharmaceutical ingredients, particularly, which are free from commercial property rights. It offers portfolio of products in various therapeutic categories including pain, women's health, cardiovascular conditions and diabetes. Few of its major generic products include including Tilidin Naloxon, Atorvastatin and Epoetin zeta. Its major branded products include APO-Go, Grippostad, Snup and Fultium. The company operates across Germany, Central Europe, CIS/Eastern Europe and Asia-Pacific. STADA is headquartered in Bad Vilbel, Germany.

Headquarters Germany

Address Stadastrasse 2-18, Bad Vilbel, Hessen, 61118


Telephone 49 6101 6030

No of Employees 12,301

Industry Pharmaceuticals and Healthcare

Revenue (2020) $779.5M

   

   

Explore premium data & analytics

690+

Marketed Drugs

Understand Stada Arzneimittel AG’s commercialized product portfolio to stay one step ahead of the market.

190+

Clinical Trials

Determine Stada Arzneimittel AG go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

15+

Catalyst Calendar

Proactively evaluate Stada Arzneimittel AG’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

14+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Stada Arzneimittel AG’s relevant decision makers and contact details.

12+

Pipeline Drugs

Identify which of Stada Arzneimittel AG’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

7

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

7

Sales & Consensus Forecasts

Understand the current and future drug revenue for Stada Arzneimittel AG and assess market opportunity for new entrants with patient population 8-year forecasts.

3

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products
Generic:
Unbranded and Branded Generics
Speciality Pharmaceuticals
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2021 Contracts/Agreements In August, the company's subsidiary, STADA MENA DWC-LLC and Crescita Therapeutics Inc entered into a commercialization and development license agreement for the rights to the topical anaesthetic cream Pliaglis.
2021 Contracts/Agreements In July, the company and Sanofi entered into a distribution agreement in which, Sanofi will distribute its consumer healthcare portfolio through STADA.
2021 Acquisitions/Mergers/Takeovers In June, the company agreed to acquire 16 consumer healthcare brands from Sanofi, a pharmaceutical company.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Stada Arzneimittel AG Vifor Pharma Ltd Evotec SE Biotest AG MorphoSys AG
Headquarters Germany Switzerland Germany Germany Germany
City Bad Vilbel St. Gallen Hamburg Dreieich Planegg
State/Province Hessen - - - -
No. of Employees 12,301 2,300 4,354 1,967 652
Entity Type Private Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Executives
Name Position Board Since Age
Peter Goldschmidt Chairman Executive Board 2018 -
Wolfgang Ollig Chief Financial Officer Senior Management 2020 -
Miguel Pagan Fernandez Chief Technical Officer Senior Management 2018 -
Frank Staud Executive Vice President - Global Communications & Branding Senior Management - -
Robert Knerr Executive Vice President - Global Portfolio & Product Development Senior Management - -
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer